Hm Payson & CO Argenx Se Transaction History

Hm Payson & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$272.01 - $353.03 $1,904 - $2,471	-7 Closed	0 $0
Q2 2021 Aug 17, 2021	SELL	$257.11 - $319.92 $12,855 - $15,996	-50 Reduced 87.72%	7 $2,000
Q4 2020 Mar 10, 2021	SELL	$248.13 - $308.36 $1,736 - $2,158	-7 Reduced 10.94%	57 $17,000
Q3 2020 Dec 21, 2020	BUY	$215.51 - $272.51 $13,792 - $17,440	64 New	64 $17,000

422

31.1M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $35.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

Stay updated on Hm Payson & CO with notifications on news.